A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
Goethe University Frankfurt · Universität Hamburg · +19 more institutions
Abstract
Coinfection with hepatitis D virus (HDV) accelerates the progression of liver disease associated with chronic hepatitis B. Bulevirtide inhibits the entry of HDV into hepatocytes. Download a PDF of the Research Summary. In this ongoing phase 3 trial, patients with chronic hepatitis D, with or without compensated cirrhosis, were randomly assigned, in a 1:1:1 ratio, to receive bulevirtide subcutaneously at 2 mg per day (2-mg group) or 10 mg per day (10-mg group) for 144 weeks or to receive no treatment for 48 weeks followed by bulevirtide subcutaneously at 10 mg per day for 96 weeks (control group). Patients will complete 96 weeks of additional follow-up after the end of treatment. The primary end point was a…
Citation impact
- FWCI
- 42.64
- Percentile
- 100%
- References
- 33
Authors
26- HWHeiner WedemeyerCorresponding
Goethe University Frankfurt, Universität Hamburg, Heidelberg University, University Hospital Heidelberg, Medizinische Hochschule Hannover, University Medical Center Hamburg-Eppendorf, German Center for Infection Research
- SASoo Aleman
University of Pisa, Goethe University Frankfurt, Karolinska University Hospital, Universität Hamburg, Heidelberg University, University Hospital Heidelberg, Karolinska Institutet, University Medical Center Hamburg-Eppendorf, German Center for Infection Research
- MRMaurizia Rossana Brunetto
Goethe University Frankfurt, Universität Hamburg, Heidelberg University, University Hospital Heidelberg, University Medical Center Hamburg-Eppendorf, German Center for Infection Research
- ABAntje Blank
Goethe University Frankfurt, Universität Hamburg, Heidelberg University, University Hospital Heidelberg, University Medical Center Hamburg-Eppendorf, German Center for Infection Research
- PAPietro Andreoné
Goethe University Frankfurt, University of Modena and Reggio Emilia, Universität Hamburg, Heidelberg University, University Hospital Heidelberg, University Medical Center Hamburg-Eppendorf, German Center for Infection Research
Topics & keywords
- Chronic hepatitis
- Randomized controlled trial
- Medicine
- Virology
- Phase (matter)
- Internal medicine
- Physics
- Virus
- Good health and well-being